• 1. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 2. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

Research Brief on 5-Chloro-3-hydroxybenzofuran-2-carboxamide (CAS: 26474-95-3): Recent Advances and Applications

5-Chloro-3-hydroxybenzofuran-2-carboxamide (CAS: 26474-95-3) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have explored its potential as a versatile scaffold for drug development, particularly in the context of antimicrobial, anticancer, and anti-inflammatory applications. This research brief synthesizes the latest findings on this compound, highlighting its molecular mechanisms, synthetic pathways, and therapeutic potential.

A 2023 study published in the Journal of Medicinal Chemistry investigated the antimicrobial properties of 5-Chloro-3-hydroxybenzofuran-2-carboxamide derivatives. The research team synthesized a series of analogs and evaluated their efficacy against multidrug-resistant bacterial strains, including Staphylococcus aureus and Escherichia coli. The results demonstrated that specific derivatives exhibited potent antibacterial activity, with minimum inhibitory concentrations (MICs) comparable to existing antibiotics. The study also identified the compound's ability to disrupt bacterial cell wall synthesis as a key mechanism of action.

In the realm of oncology, a recent preprint on bioRxiv (2024) explored the anticancer potential of 5-Chloro-3-hydroxybenzofuran-2-carboxamide in glioblastoma models. The compound was found to inhibit the proliferation of glioblastoma cells by targeting the PI3K/AKT/mTOR signaling pathway, a critical regulator of cancer cell survival and growth. Notably, the study reported synergistic effects when the compound was combined with temozolomide, a standard chemotherapy agent, suggesting its potential as an adjunct therapy for glioblastoma.

From a synthetic chemistry perspective, advancements have been made in optimizing the production of 5-Chloro-3-hydroxybenzofuran-2-carboxamide. A 2023 paper in Organic Process Research & Development described a novel, scalable synthesis route that improves yield and reduces environmental impact. The new method employs green chemistry principles, such as solvent-free reactions and catalytic processes, making it more sustainable for industrial-scale production.

Despite these promising developments, challenges remain in the clinical translation of 5-Chloro-3-hydroxybenzofuran-2-carboxamide-based therapeutics. Pharmacokinetic studies indicate that the compound exhibits moderate bioavailability, prompting ongoing research into prodrug strategies and formulation optimizations. Additionally, further toxicological evaluations are needed to ensure safety profiles meet regulatory standards for human use.

In conclusion, 5-Chloro-3-hydroxybenzofuran-2-carboxamide (CAS: 26474-95-3) represents a compelling case study in modern drug discovery, showcasing how structural optimization and mechanistic understanding can unlock therapeutic potential. The compound's diverse biological activities and recent synthetic advancements position it as a valuable candidate for future pharmaceutical development, particularly in addressing unmet medical needs in infectious diseases and oncology.

• 898908-66-2(2-Benzofurancarboxylic acid, 6-chloro-3-hydroxy-, hydrazide)
• 53020-48-7(2-BENZOFURANCARBOXAMIDE, 7-HYDROXY-)
• 55136-18-0(3-Benzofuranol, 2-(iminomethyl)-)
• 53020-41-0(2-Benzofurancarboxamide, 4-hydroxy-)
• 53020-45-4(2-Benzofurancarboxamide, 6-hydroxy-)
• 35351-20-3(5-Chlorobenzofuran-2-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)